[Gastrointestinal cancer antigen and carcinoembryonic antigen in chronic pancreatopathies and pancreatic tumors].
Sensitivity and specificity of the Ca 19-9 (GICA) marker was evaluated in series of pancreatic cancer patients, chronic pancreatitis patients and normal controls. When Ca 19-9 was compared with CEA, it was noted that the new marker was far more sensitive and specific than CEA (82% v. 52% sensitivity, 95% v. 80% specificity). GICA was found to be the best marker for pancreatic tumors.